We describe the liquid-chromatographic determination of ciprofloxacin in patients' serum and urine. Serum samples were prepared by precipitating protein with perchloric acid. Urine samples were diluted 100-fold with mobile phase. The mobile phase, consisting of pH 3 phosphate buffer/acetonitrile/methanol (81/5/14, by vol), was pumped through a Bondapak C18 reversed-phase column at 1.5 mL/min. Fluorescence of the effluent was monitored, at wavelengths for excitation and emission of 270 and 440 nm, respectively. Standard curves were linearly related to concentration from 0.08 to 10 mg/L for serum, 1 to 20 mg/L for urine. The procedure was evaluated in a clinical setting to determine Its usefulness in studying the pharmacoklnetics of ciprofloxacin in patients with concurrent diseases and receiving multiple drug therapies. Strains of Enterobacteriaceae and P. aeruginosa resistant to aininoglycosides and of S. aureus resistant to methicillin are usually susceptible to ciprofloxacin (2). Ciprofloxacin, administered orally, reaches peak concentrations in serum of 1.1 mgfL by 1.0 to 1.5 h after a 250-mg dose (3). Proportionally higher peak concentrations in serum (2.1 mg/L) have been reported when a 500-mg tablet was administered and a microbiological assay was used (4).
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Although liquid-chromatographic assays have been developed for ciprofloxacin (3, 5) , these did not include an internal standard. We describe here a simple, precise, and inexpensive liquid-chromatographic assay in which an internal standard is used.
Materials and Methods
Reagents. All chemicals and reagents were analytical grade. De-ionized distilled water was used throughout.
Ciprofloxacin
(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- Co., Avondale, PA 19311) were used. Mobile phase consisted of pH 3 phosphate buffer/acetomtrile/methanol, 81/5/14 by vol. The phosphate buffer was prepared freshly each day and contained monobasic potassium phosphate (20 mmol/L), tetrabutylanimonium hydroxide (5 mmolIL), and phosphoric acid (6 mmol/L) in water. The mobile phase was pumped through an octadecylsilane column (jiBondapak C15; Waters Associates) at 1.5 mLfmin. Excitation and emission wavelengths were 270 and 440 nm, respectively. An attentuation of 1.0 A full scale was used.
Extraction procedure. To 0.5 mL of serum in aS X 13 mm After sample preparation, we observed no change in the peak-area ratio of ciprofioxacin to internal standard in 24 h.
When prepared samples of serum and urine were stored frozen, there was no change in the peak-area ratio of ciprofloxacin to internal standard after two months.
Analytical recovery and precision. Analytical recovery was determined by adding ciprofloxacin to fresh serum and to a solution of mobile phase, to yield concentrations of 0.4 and 4.0 mg/L, then analyzing. The serum standards were treated as described above, but with no internal standard added.
Recovery was calculated by dividing the average ciprofloxacin area for prepared serum-based standards by that obtained from direct injection of volume-adjusted standards in mobile phase. Four determinations were made at each concentration.
Within-day variation was determined by assaying three standard serum samples (0.4, 1, and 10 mg/L) five times each. Also, we assayed 0.4, 1, and 10 mg/L samples on four occasions, at least 24 h apart, in different runs, to determine between-day variation. Within-and between-day variation was determined for urine standards containing 1.0 and 20 mg of ciprofloxacin per liter.
Patients' samples. Serum and urine samples were obtained from patients who were being treated with ciprofioxacm, 500mg every 12 h, for infection of soft tissue or bone.
The profile for drug concentration in serum vs time shown in Figure 2 and the renal clearance proffle in Figure 3 are typical examples of patients evaluated. The patients often had concurrent medical conditions such as renal impairment, diabetes mellitus, congestive heart failure, angina, and chronic obstructive pulmonary disease.
Quantification.
Standards
for serum and urine ranging from 0.08 to 10 mg/L and 1.0 to 20 mg/L, respectively, were used to produce standard curves. Concentrations of ciprofloxacin in serum were determined by determining the ratio of the peak area for the drug to that for the internal standard, then comparing with the standard curves obtained after linear regression analysis of the calibration samples. Figure 2 shows the concentrations of ciprofloxacin in plasma at steady-state from a patient who had received 500 mg orally every 12 h. The concentration was greatest about 1.5 h after the dose; the apparent biological half-life in plasma, as calculated by linear regression analysis, was 6.3 h. Because clinical monitoring is the usual goal of most drug assays, we checked for possible drug or serum interferences. The assay was evaluated in 16 hospitalized and nonhospitalized patients who were receiving ciprofloxacin for infection of soft tissue or bone. Each patient had the serum samples drawn at the following times after their seventh to ninth dose of ciprofloxacin: 0,0.25,0.5, 0.75, 1, 2, 3, 5, 7, 9, and 12 h. Urine-collection intervals were 0-3,3-6,6-9, and 9-12 h after the same dose. The patients had various disorders in addition to infection, and they were taking other drugs such as codeine, digoxin, furosemide, meperidine, insulin, methyldopa, temazepam, diphenhydramine, cimetidine, rarntidine, spironolactone, metoclopramide, hydroxyzine, and prochlorperazine. No serum or urine samples obtained from these patients before ciprofloxacin administration showed interference.
Discussion
Pharmacokinetic parameters for ciprofloxacin have varied widely in patients of various ages and various concurrent diseases, As with many drugs, an assay is needed for monitoring patients and for evaluating differences in pharmacokinetics. The assay described here is relatively simple. The broad elution peak for ciprofloxacin suggests that the column efficacy is suboptimal, the number of theoretical plates being approximately 1000; this appears to be a problem with this class of drugs. However, ciprofloxacin is well resolved from the internal standard and other substances, and results are accurate and reproducible. Metabolites of this drug are not available, so we could not assess their chromatographic behavior. Other investigators have compared results of liquid-chromatographic and microbiological assays and found essentially the same values for concentrations of ciprofloxacin in serum, but those in urine were 50 to 60% higher by the microbiological methods (5),
suggesting the presence of an active metabolite. Ciprofloxacin is adsorbed to glass, and we initially noted carryover of ciprofloxacin with the use of a manual syringe.
Although this problem was resolved by washing the syringe with water between injections, nevertheless a separate syringe should be used for stock solutions to avoid exposing the injection syringe to high concentrations of the drug, because carryover may occur even with several washes after such high concentrations are used. We used polypropylene containers whenever possible. Carryover presents a problem only when one is attempting to measure low (<0.1 mgIL)
concentrations of ciprofloxacin. When serum containing 4
.&gof ciprofloxacin per milliliter was placed in glass, siliconized glass, and polypropylene tubes, we found no significant differences in the measured concentrations.
In our present investigations, a minimal detectable concentration of 0.08 mg/L was adequate. Because of potential carryover, the reliability of concentrations below 0.1 mgfL should be investigated before they are reported. In the present assay, use of an emission ifiter with a 370-nm cutoff increased the relative peak area for ciprofloxacin by 190% and for the internal standard by 150%. Thus use of such a ifiter can provide increased sensitivity if required.
